arXiv:2605.31562v1 Announce Type: new Abstract: RNA sequencing produces rich and diverse datasets of gene expression, offering compelling insights into cellular state and function that have many applications in drug discovery. Modeling such data is challenging due to inherent technical noise and experimental batch effects, as evidenced by many existing transcriptomic foundation models (FMs) underperforming relative to linear baselines. Such results raise the question of whether deep representation learning provides a distinct advantage over the direct use of raw transcript counts. Our work exp
The proliferation of RNA sequencing data and advancements in large language models for biological data are creating new opportunities for deeper insights into cellular function.
Improving the efficacy of biological representation learning can significantly accelerate drug discovery and our understanding of disease mechanisms, impacting global health and biopharmaceutical innovation.
This research suggests a more effective approach to modeling gene expression data, potentially overcoming current limitations of existing transcriptomic foundation models and leading to more robust biological insights.
- · Biopharmaceutical companies
- · AI/ML researchers in biology
- · Patients with complex diseases
- · Biotech startups
- · Companies relying on less effective traditional gene expression analysis
- · Research groups without access to advanced computational resources
More accurate and efficient drug target identification and validation become possible.
The cost and timeline for developing new therapeutics could decrease, leading to a surge in novel treatment options.
Personalized medicine approaches might become significantly more sophisticated, tailoring treatments based on individual genomic and transcriptomic profiles.
This signal links to a primary source. Continuum Brief monitors and indexes it as part of the live intelligence stream — we do not republish source content.
Read at arXiv cs.LG